These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25214286)

  • 1. Dopaminergic agents and nutritional status in Parkinson's disease.
    Laudisio A; Vetrano DL; Meloni E; Ricciardi D; Franceschi F; Bentivoglio AR; Bernabei R; Zuccalà G
    Mov Disord; 2014 Oct; 29(12):1543-7. PubMed ID: 25214286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopaminergic effects on cognitive performance in patients with Parkinson's disease.
    Lange KW; Paul GM; Naumann M; Gsell W
    J Neural Transm Suppl; 1995; 46():423-32. PubMed ID: 8821078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutritional risk and gastrointestinal dysautonomia symptoms in Parkinson's disease outpatients hospitalised on a scheduled basis.
    Barichella M; Cereda E; Madio C; Iorio L; Pusani C; Cancello R; Caccialanza R; Pezzoli G; Cassani E
    Br J Nutr; 2013 Jul; 110(2):347-53. PubMed ID: 23228187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and therapy of Parkinson's disease].
    Wittstock M; Benecke R
    MMW Fortschr Med; 2005 May; 147 Spec No 2():28-31. PubMed ID: 15968869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing dopaminergic therapy of Parkinson's disease.
    Horowski R
    Funct Neurol; 1988; 3(4):459-70. PubMed ID: 2907501
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevalence of malnutrition in patients with Parkinson's disease: a comparative study with healthy controls using Mini Nutritional Assessment (MNA) questionnaire.
    Fereshtehnejad SM; Ghazi L; Sadeghi M; Khaefpanah D; Shahidi GA; Delbari A; Lökk J
    J Parkinsons Dis; 2014; 4(3):473-81. PubMed ID: 24718272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson's disease.
    Chahine LM; Daley J; Horn S; Duda JE; Colcher A; Hurtig H; Cantor C; Dahodwala N
    Parkinsonism Relat Disord; 2013 Oct; 19(10):859-63. PubMed ID: 23751512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and nutritional correlations in Parkinson's disease: Preliminary report.
    Budrewicz S; Zmarzły A; Rączka D; Szczepańska A; Koziorowska-Gawron E; Słotwiński K; Koszewicz M
    Adv Clin Exp Med; 2019 Feb; 28(2):193-198. PubMed ID: 29963785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological gambling in two patients on dopamine replacement therapy for Parkinson's disease.
    Avanzi M; Uber E; Bonfà F
    Neurol Sci; 2004 Jun; 25(2):98-101. PubMed ID: 15221629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mini Nutritional Assessment in patients with Parkinson's disease: correlation between worsening of the malnutrition and increasing number of disease-years.
    Barichella M; Villa MC; Massarotto A; Cordara SE; Marczewska A; Vairo A; Baldo C; Mauri A; Savardi C; Pezzoli G
    Nutr Neurosci; 2008 Jun; 11(3):128-34. PubMed ID: 18616869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors contributing to malnutrition in patients with Parkinson's disease.
    Kim SR; Chung SJ; Yoo SH
    Int J Nurs Pract; 2016 Apr; 22(2):129-37. PubMed ID: 25521723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease?
    Lipski J; Nistico R; Berretta N; Guatteo E; Bernardi G; Mercuri NB
    Prog Neurobiol; 2011 Sep; 94(4):389-407. PubMed ID: 21723913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypersexuality during use of levodopa].
    van Deelen RA; Rommers MK; Eerenberg JG; Egberts AC
    Ned Tijdschr Geneeskd; 2002 Nov; 146(44):2095-8. PubMed ID: 12448966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The thrill of reckless driving in patients with Parkinson's disease: an additional behavioural phenomenon in dopamine dysregulation syndrome?
    Avanzi M; Baratti M; Cabrini S; Uber E; Brighetti G; Bonfà F
    Parkinsonism Relat Disord; 2008; 14(3):257-8. PubMed ID: 17561433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.